Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.27%
#2 aelf aelf +23.35%
#3 Bitway Bitway +15.70%
#4 Decred Decred +10.92%
#5 Pons Pons +10.14%
#6 TRIA TRIA +9.37%
#7 Wibx Wibx +8.11%
#8 AtomOne AtomOne +7.63%
#9 DexNet DexNet +7.56%
#10 Status Status +7.21%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Kedudukan dalam Saham #30835
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Harga Saham
$0.089
Disegerakkan terakhir: 2026-08-17
Modal Pasaran
$15.36M
Perubahan (1 hari)
50.59%
Perubahan (1 tahun)
72.65%
Negara
US
Perdagangan Inhibitor Therapeutics, Inc. (INTI)

Kategori

Healthcare
Pendapatan untuk Inhibitor Therapeutics, Inc. (INTI)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Inhibitor Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Inhibitor Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE